Adjuvant cytokine-induced killer cell immunotherapy in hepatocellular carcinoma: real-world data and 9-year extended follow-up of a randomized controlled trial
Adjuvant CIK cell therapy significantly improved RFS in both a RWD study and a 9-year extended RCT follow-up, supporting its reproducible benefit in reducing recurrence after curative treatment of HCC. These consistent findings provide strong evidence for the clinical utility of CIK therapy as a durable adjuvant immunotherapeutic strategy for HCC.
Authors
- Jong-Eun Yeon
- Moon Haeng Hur
- Youngwoo Lee
- Yoon Jun Kim
- Joon Hyeok Lee
- Eun Ju Cho
- Yun Bin Lee
- Byeong Geun Song
- Tae-Jin Song
- Hyung Joon Han
- Hyunjae Shin
- Jung-Hwan Yoon
- Youngsu Park
- Won-Mook Choi
- Young-Suk Lim
- Su Jong Yu
- Jeong-Hoon Lee
Institutions
- Ulsan College (KR)
- Seoul National University (KR)
- Korea University Medical Center (KR)
- Asan Medical Center (KR)
- Samsung Medical Center (KR)
- New Generation University College (ET)
- Ansan University (KR)
- University of Ulsan (KR)
- National Cancer Center (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2026-01-27
- DOI
- https://doi.org/10.1007/s00262-026-04301-6
- Citations
- 1
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 24.43